Tauopathies, known as neurodegenerative disorders, are characterized by abnormal tau protein deposition in the brain, and MAPT expression is a biomarker for tauopathies and an increased survival rate and low-grade glioma (Zaman et al., 2019). This evidence concerns the gene MAPT and central nervous system cancer.